Changes in Iron Metabolism and Oxidative Status in STZ-Induced Diabetic Rats Treated with Bis(maltolato) Oxovanadium (IV) as an Antidiabetic Agent

Table 1

Digestive and metabolic utilization of Fe on days 28–35 of study.

	C	DM	DMV	DMVH	𝑃test
Food intake (g/day)	15 ± 2	33 ± 2.4^a	26.9 ± 2^a,b	13.8 ± 1.1^b,c	𝑃<0.001
Water intake (mL/day)	17 ± 4	324 ± 36^a	191 ± 41^a,b	14 ± 7^b,c	𝑃<0.001
V intake (µg/day)	1 ± 0.1	1.9 ± 0.1^a	965 ± 104^a,b	3228 ± 350^a,b,c	𝑃<0.001
Fe intake (𝐼) (µg/day)	668 ± 88	1472 ± 105^a	1197 ± 89^a,b	614 ± 50^b,c	𝑃<0.001
Faecal excretion (𝐹) (µg/day)	497 ± 75	1219 ± 106^a	888 ± 50^a,b	430 ± 78^b,c	𝑃<0.001
Urinary excretion (𝑈) (µg/day)	29 ± 8	118 ± 95^a	103 ± 22^a	47 ± 17^a,b,c	𝑃<0.001
Absorbed (𝐴); 𝐴=(𝐼−𝐹) (µg/day)	171 ± 78	253 ± 56^a	308 ± 68^a	184 ± 59^b,c	𝑃<0.01
Retained (𝑅); 𝑅=[𝐼−(𝐹+𝑈)] (µg/day)	142 ± 79	134 ± 52	205 ± 66^b	137 ± 64^c	NS

Values shown are means ± SD, C: control rats; DM: diabetic STZ rats; DMV: diabetic STZ rats treated with 1 mgV/day; DMVH: diabetic STZ rats treated with 3 mgV/day. ^aDifferent from group C; ^bdifferent from group DM; ^cdifferent from group DMV. P < 0.05. NS: not significant.